PrEP Biopharm Limited : announces addition of Jim Cornelius and Clive Page to its Board of Directors

LONDON, Aug. 11, 2016 /PRNewswire/ — PrEP Biopharm Limited, a particular independent drug development company for respiratory infectious disease products, announced that Jim Cornelius, former chairman and CEO of Bristol-Myers Squibb, and Clive Page, PhD, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology at King’s College London, consider joined the company’s Board of Directors. They fetch expansive strategic, operational and scientific experience to the Board.

Mr. Cornelius brings a 40-year footstep record of successful management in the life sciences. He is currently the Chairman of Mead-Johnson Nutrition and in etc. to his role at Bristol-Myers Squibb, he antecedently served as the Chairman and CEO of Guidant Corp, CFO of Eli Lilly and Co and of the same kind with a director at a dozen common and private companies, including The Chubb Corporation and The DIRECTV Group.

Dr. Page is a world renown expert in the pharmacology of inflammation and respiratory disease who has published greater quantity than 250 scientific articles and serves forward the board of directors or scientific advisory board of eleven innovative biotechnology companies.

“I’m thrilled to greet Jim and Clive to PrEP Biopharm’s Board,” reported Ryan Muldoon, CEO of PrEP Biopharm. “As ~y investor in our series A on all sides, Jim has been with us since our inception, previously serving as every advisor to the Board. His fortune of experience at life science companies the couple large and small will help PrEP Biopharm one as well as the other strategically and operationally. Clive’s decades of experience in drug development and deep brains of the biology of inflammation and respiratory infirmity will be a tremendous asset to PrEP like we continue our Phase 2 drudge on PrEP-001 for the prevention of upper respiratory viral infections.”

“I’m excited to join PrEP Biopharm’s Board of Directors and face forward to contributing my insights and helping to figure the company,” said Mr. Cornelius. “I’m impressed by the data from PrEP-001 in the way that far and the potential that this physic holds for addressing a variety of respiratory viruses, the greater number of which have no approved treatments or vaccines.”

“I’ve spent my career looking for ways to expertness respiratory disease,” said Dr. Page. “PrEP Biopharm has tend hitherward up with a novel approach and be in possession of an exciting technology in PrEP-001. I chance of the desired end to help them shape their bring near and development to address an increasingly of importance unmet need in respiratory viral diseases.”

About PrEP Biopharm Limited:

Prep Biopharm Limited is one independent, development stage biopharmaceutical company focused put ~ the prevention of respiratory infections. The privately held company’s flagship product, PrEP-001, is in appearance 2 for the prevention of upper respiratory pamphlet viral infections.

To view the oddity version on PR Newswire, visit: accounts-releases/prep-biopharm-limited-announces-etc.-of-jim-cornelius-and-clive-page-to-its-board-of-directors-300312023.html

SOURCE PrEP Biopharm Limited

So, according to Jefferson, in that place could be such a thing viewed like a “white slave” – a leading predicate that included his own children, including his alone surviving sons! Fratti-Newman Political Play Contest and funded ~ dint of. an Art Works grant from the National Endowment on account of the Arts) receives its globe premiere March 8-18, 2012 at Plan-B Theatre Company.

Recent Comments